Thousand Oaks biotech giant Amgen announced a new approval in China on Jan. 24 for its cardiovascular drug Repatha as well as positive new data for its rheumatoid arthritis biosimilar ABP 798. The National Medical Products Administration approval of Repatha makes it the first PCSK9 inhibitor approved in China for use in adults with atherosclerotic…
This article is only available to Business Times subscribers
Subscribers: LOG IN or REGISTER for complete digital access.
Not a Subscriber? SUBSCRIBE for full access to our weekly newspaper, online edition and Book of Lists.
